Current therapeutic landscape of β-thalassemia: focus on gene therapy
Open Access
- 28 March 2026
- journal article
- Published by SAGE Publications in Therapeutic Advances in Rare Disease
- Vol. 7
Abstract
β-thalassemia is an inherited blood disorder characterized by chronic anemia, ineffective erythropoiesis, and in its most severe form, lifelong transfusion dependence. The standard of care for transfusion-dependent thalassemia (TDT) is regular red blood cell transfusions to relieve the anemia and suppress ineffective erythropoiesis and iron chelation therapy to mitigate morbidity and mortality related to iron overload. Allogeneic hematopoietic stem cell transplantation is a curative option but is only available to patients with an appropriate donor and carries risks of graft-versus-host disease and other transplant-related morbidity. In recent years, the therapeutic landscape for TDT has changed dramatically with the approval of two autologous gene therapies in the United States: betibeglogene autotemcel (beti-cel) and exagamglogene autotemcel (exa-cel). Clinical trials for both gene therapies have demonstrated high rates of sustained transfusion independence for both pediatric and adult age groups. However, despite these advances, challenges remain. Gene therapy requires myeloablative busulfan-based conditioning chemotherapy, which carries the risk of short- and long-term toxicities. Furthermore, centralized manufacturing and high treatment costs are likely to limit access to gene therapy. In this review, we discuss the available clinical trial and real-world data for beti-cel and exa-cel. We describe how gene therapy fits into the current treatment landscape and introduce areas of ongoing investigation to improve access to transformative therapy for TDT.Keywords
Funding Information
- Penn Hematology
This publication has 58 references indexed in Scilit:
- Polymorphisms in the Immunoregulatory Genes are Associated with Hematopoietic Recovery and Increased Susceptibility to Bacterial Infections in Patients with Thalassaemia Major Undergoing Matched Related Hematopoietic Stem Cell TransplantationTransplantation and Cellular Therapy, 2012
- Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfanBlood, 2012
- Correction of Sickle Cell Disease in Adult Mice by Interference with Fetal Hemoglobin SilencingScience, 2011
- Pregnancy outcomes in women with elevated levels of fetal hemoglobinThe Journal of Maternal-Fetal & Neonatal Medicine, 2011
- Control of fetal hemoglobin: new insights emerging from genomics and clinical implicationsHuman Molecular Genetics, 2009
- Human Fetal Hemoglobin Expression Is Regulated by the Developmental Stage-Specific Repressor BCL11AScience, 2008
- DNA polymorphisms at the BCL11A , HBS1L-MYB , and β- globin loci associate with fetal hemoglobin levels and pain crises in sickle cell diseaseProceedings of the National Academy of Sciences, 2008
- Genome-wide association study shows BCL11A associated with persistent fetal hemoglobin and amelioration of the phenotype of β-thalassemiaProceedings of the National Academy of Sciences, 2008
- A QTL influencing F cell production maps to a gene encoding a zinc-finger protein on chromosome 2p15Nature Genetics, 2007
- Molecular Basis of Hereditary Persistence of Fetal HemoglobinAnnals of the New York Academy of Sciences, 1998